ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript March 20, 2025
ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, expectations were $-0.04.
Justin Chakma – Chief Business Officer:
Richard Lowenthal – Co-Founder, President and CEO:
Eric Karas – Chief Commercial Office:
Kathleen Scott – CFO:
Ryan Deschner – Raymond James:
Alexa Deemer – Cantor Fitzgerald:
Louise Chen – Scotia Bank:
Roanna Ruiz – Leerink Partners:
Lachlan Hanbury-Brown –...
